Esculentoside a attenuates airway inflammation in asthma by regulating mitochondrial apoptosis via the JAK2/STAT3 pathway
Main Article Content
Keywords
esculentoside A, asthma, JAK2/STAT3, mitochondrial apoptosis, airway inflammation
Abstract
Objective: This study aimed to investigate whether esculentoside A (EsA) alleviates airway inflammation by modulating JAK2/STAT3-mediated mitochondrial apoptosis in an ovalbumin (OVA)-induced murine model of asthma.
Methods: Female BALB/c mice were sensitized and challenged with OVA to establish the asthma model. EsA (15 mg/kg) was administered intraperitoneally from day 17 for seven consecutive days. JAK2 inhibitor (Fedratinib, 60 mg/kg) and JAK2 agonist (C-A1, 100 μg/kg) were used to further validate the involvement of the JAK2/STAT3 pathway. Histological analysis, ELISA, Western blot, TUNEL, and mitochondrial function assays were performed to evaluate inflammatory response, apoptosis, and signaling pathways.
Results: EsA treatment significantly alleviated airway inflammation, as shown by reduced peribronchial inflammatory infiltration and lower inflammation scores, and decreased goblet cell hyperplasia and PAS staining scores. ELISA results showed that EsA significantly reduced IL-4, IL-13, and TNF-β levels in BALF and decreased serum OVA-specific IgE. Western blot revealed that EsA downregulated phosphorylated JAK2 and STAT3 levels, as well as proapoptotic markers (Bax, Cyt C, and cleaved Caspase-3), while upregulating the antiapoptotic protein Bcl-2. These effects were comparable to those of Fedratinib and were reversed by JAK2 agonist C-A1. Furthermore, EsA restored mitochondrial membrane potential (JC-1 ratio increased) and reduced mitochondrial ROS production, indicating improved mitochondrial function. TUNEL assays corroborated the antiapoptotic effect of EsA.
Conclusion: EsA ameliorates OVA-induced airway inflammation in mice, likely by suppressing the JAK2/STAT3 signaling pathway and attenuating mitochondrial-dependent apoptosis. These findings suggest that EsA holds therapeutic potential as a novel anti-asthmatic agent targeting inflammatory and mitochondrial pathways.
References
2 Gruffydd-Jones K. Unmet needs in asthma. Ther Clin Risk Manag. 2019;15:409–421. 10.2147/TCRM.S160327
3 Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. Pulm Pharmacol Ther. 2015 Aug;33:1–10. 10.1016/j.pupt.2015.05.006
4 Perez de Llano L, et al. Phenotype-guided asthma therapy: an alternative approach to guidelines. J. Asthma Allergy. 2021;207–217. 10.2147/JAA.S266999
5 M Adcock I, et al. Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD). Curr. Pharm. Des. 2010;16(32):3554–3573. 10.2174/138161210793797889
6 White SR. Apoptosis and the airway epithelium. J Allergy (Cairo). 2011;2011:948406. 10.1155/2011/948406
7 Qian L, et al. Mitochondria signaling pathways in allergic asthma. J. Investig. Med 2022;70(4):863–882. 10.1136/jim-2021-002098
8 Yu H, et al., Apigenin ameliorates non-eosinophilic inflammation, dysregulated immune homeostasis and mitochondria-mediated airway epithelial cell apoptosis in chronic obese asthma via the ROS-ASK1-MAPK pathway. Phytomedicine. 2023;111:154646. 10.1016/j.phymed.2023.154646
9 Tesfaigzi Y, Roles of apoptosis in airway epithelia. Am. J. Respir. Cell Mol. Biol. 2006;34(5):537–47. 10.1165/rcmb.2006-0014OC
10 Yu H, et al. Transcriptomics reveals apigenin alleviates airway inflammation and epithelial cell apoptosis in allergic asthma via MAPK pathway. Phytotherapy Research. 2023;37(9):4002–4017. 10.1002/ptr.7859
11 Chellappan DK, et al. Targeting the mitochondria in chronic respiratory diseases. Mitochondrion. 2022;67:15–37. 10.1016/j.mito.2022.09.003
12 Purohit M, et al. Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in lung inflammatory disease. Chem. Biol. Interact. 2023;371:110334. 10.1016/j.cbi.2023.110334
13 Nikolskii AA et al. Role of STAT3 transcription factor in pathogenesis of bronchial asthma. Biochemistry (Moscow) 2021;86(11): 1489–1501. 10.1134/S0006297921110122
14 Vale K. Targeting the Jak-Stat pathway in the treatment of ‘Th2-high’ severe asthma. Future Med. Chem. 2016;8(4): 405–419. 10.4155/fmc.16.4
15 Bai H, et al. β-Asarone alleviates allergic asthma by stabilizing mast cells through inhibition of ERK/JAK2-STAT3 pathway. BioFactors. 2023;49(1):140–152. 10.1002/biof.1879
16 Kasembeli MM, et al. Contribution of STAT3 to inflammatory and fibrotic diseases and prospects for its targeting for treatment. Int. J. Mol. Sci.. 2018;19(8):2299. 10.3390/ijms19082299
17 Farmanzadeh A, Qujeq D, Yousefi T. The interaction network of MicroRNAs with cytokines and signaling pathways in allergic asthma. MicroRNA. 2022;11(2):104–117. 10.2174/2211536611666220428134324
18 Sen A. Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases. World J. Clin. Cases. 2020;8(10): 1767–1792. 10.12998/wjcc.v8.i10.1767
19 Ghosh S, Roy K, Pal C. Terpenoids against infectious diseases, in Terpenoids against human diseases. 2019. CRC Press. p. 187–208. 10.1201/9781351026703-8
20 Bai D, et al., Leonurine attenuates OVA-induced asthma via p38 MAPK/NF-κB signaling pathway. Int. Immunopharmacol. 2023;114:109483. 10.1016/j.intimp.2022.109483
21 Jie XL, et al. Pi-Pa-Run-Fei-Tang alleviates lung injury by modulating IL-6/JAK2/STAT3/IL-17 and PI3K/AKT/NF-κB signaling pathway and balancing Th17 and Treg in murine model of OVA-induced asthma. J. Ethnopharmacol. 2023;317:116719. 10.1016/j.jep.2023.116719
22 Ren Y, et al. Zhike pingchuan granules improve bronchial asthma by regulating the IL-6/JAK2/STAT3 pathway. Exp. Ther. Med. 2021; 22(2):899. 10.3892/etm.2021.10331
23 Bai D, et al. Leonurine attenuates OVA-induced asthma via p38 MAPK/NF-kappaB signaling pathway. Int. Immunopharmacol. 2023;114:109483. 10.1016/j.intimp.2022.109483
24 Jie XL, et al. Pi-Pa-Run-Fei-Tang alleviates lung injury by modulating IL-6/JAK2/STAT3/IL-17 and PI3K/AKT/NF-kappaB signaling pathway and balancing Th17 and Treg in murine model of OVA-induced asthma. J. Ethnopharmacol. 2023;317: 116719. 10.1016/j.jep.2023.116719
25 Dong L, et al. Hypoxic hUCMSC-derived extracellular vesicles attenuate allergic airway inflammation and airway remodeling in chronic asthma mice. Stem. Cell Res. Ther. 2021;12(1):4. 10.1186/s13287-020-02072-0
26 Liu Y, et al. Esculentoside A could attenuate apoptosis and inflammation in TNBS-induced ulcerative colitis via inhibiting the nuclear translocation of NF-kappaB. Ann. Transl. Med. 2022;10(14): 771. 10.21037/atm-22-2675
27 Wu J, et al. Esculentoside A exerts anti-oxidative stress and anti-apoptotic effects in rat experimental membranous nephropathy by regulating MAPK pathway. Molecular & Cellular Toxicology. 2022; 18(3):321–327. 10.1007/s13273-021-00194-x
28 Samad MA, et al. STAT3 signaling pathway in health and disease. MedComm. 2025;6(4):e70152. 10.1002/mco2.70152
29 Athari SS. Targeting cell signaling in allergic asthma. Signal transduct. target. ther. 2019;4(1):45. 10.1038/s41392-019-0079-0
30 Liu Y, et al. Esculentoside A could attenuate apoptosis and inflammation in TNBS-induced ulcerative colitis via inhibiting the nuclear translocation of NF-κB. Ann. Transl. Med. 2022;10(14): 771. 10.21037/atm-22-2675